Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
Sundar JagannathCarolyn C JacksonJordan M SchecterNikoletta LendvaiHuabin SunMuhammad AkramNitin PatelThomas G MartinPublished in: Expert opinion on biological therapy (2024)
CAR-T therapies can improve outcomes for patients with MM across different LOTs. CARTITUDE-1 and CARTITUDE-4 have set a new bar for efficacy, with median PFS of 34.9 months in heavily pretreated patients (CARTITUDE-1) and a 74% relative risk reduction for progression/death versus standard care in patients with 1-3 prior LOTs (CARTITUDE-4), with manageable safety. Response rates were consistent between the two studies: 98% in CARTITUDE-1 and approaching 100% for infused patients in CARTITUDE-4. Cilta-cel could be a key treatment choice for patients with RRMM after first LOT. Clinical trials investigating frontline cilta-cel therapy will provide valuable insights into optimizing treatment pathways with the aim to potentially cure MM.
Keyphrases
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- multiple myeloma
- prognostic factors
- randomized controlled trial
- stem cells
- type diabetes
- mesenchymal stem cells
- cancer therapy
- insulin resistance
- bone marrow
- cell therapy
- quality improvement
- double blind
- chemotherapy induced